TrialThe Journal of infectious diseases2010

Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial.

David M Asmuth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.